|
|
||||||||
ORIGINAL CONTRIBUTION |
From the Department of Obstetrics and Gynecology at Oklahoma State University Center for Health Sciences and College of Osteopathic Medicine and Surgery in Tulsa (Drs Breese McCoy and Beal), from the Department of Statistics at Oklahoma State University in Stillwater (Dr Payton), from the Department of Neonatology at the University of Arkansas for Medical Sciences in Little Rock (Dr Stewart), from Ingham Regional Medical Center in Lansing, Mich (Dr DeMers), and from the Georgia Campus–Philadelphia College of Osteopathic Medicine in Suwanee (Dr Watson).
Address correspondence to Sarah J. Breese McCoy, PhD, Office of Research, OSU Center for Health Sciences, 1111 W 17th St, Tulsa, OK 74107-1898.E-mail: sjmccoy98{at}aol.com
Context: While correlations have been demonstrated between postpartum depression and psychosocial and circumstantial risk factors, some evidence exists for a similar relationship between postpartum depression and thyroid measures.
Objective: To search at 4 weeks postpartum for correlations of numerical scores on a postnatal depression screening tool and thyroid measures.
Methods: Subjects took the Edinburgh Postnatal Depression Scale (EPDS) prenatally and at 4 weeks postpartum. Participants were also given blood tests for thyroid-stimulating hormone (TSH), free thyroxine4, thyroid peroxidase, and thyroglobulin at the same testing intervals.
Results: Fifty-one subjects aged 18 years or older were recruited. Subjects with higher serum TSH at 4 weeks postpartum tended to have higher EPDS scores. Similarly, the 7 subjects (13.7%) with positive postnatal thyroid antibody tests were more likely than their counterparts to have higher EPDS scores.
Conclusions: Presence of thyroid autoantibodies or higher TSH levels during the postpartum period may be related to depressive symptoms or dysphoric mood, even when clinical depression is not present. Either or both of these associations may contribute, along with other physiologic and psychosocial risk factors, to postpartum depression. (ClinicalTrials.gov number NCT00565032 [ClinicalTrials.gov] )
Most research12 aimed at uncovering a relationship between PPD and thyroid measures has categorized women as either "depressed" or "not depressed." However, depressive symptoms rated numerically along a continuum have also been used by previous researchers.7
The present pilot study was undertaken to corroborate a relationship between quantified mood and thyroid measures. Numerical scores obtained from a common depression screening tool, the Edinburgh Postnatal Depression Scale (EPDS),8 were compared with the presence of thyroid autoantibodies and plasma concentrations of TSH and free T4 (FT4).
| Methods |
|---|
|
|
|---|
Exclusion criteria were used to ensure a relatively uniform sample of women who were not depressed, who were not taking mood-altering medications, and whose prenatal hormone levels were not substantially different from the mean. Subjects were required to score no higher than 12 on the EPDS prenatally and pass a drug screen. In addition, we ensured that potential subjects were not carrying twins and did not plan to deliver by cesarean section.
Study protocols and informed consent agreements were reviewed and approved by the OSUCHS Institutional Review Board before study initiation. Patient confidentiality was closely guarded. Once recorded, data were reported in the completed study as mean scores of all participants. Volunteers were paid for their participation.
Subject Testing
At the prenatal and 4-week postpartum physician visits, subjects were asked
to take the self-administered EPDS with pencil and paper before the blood
draw. At both testing intervals, subjects' blood was drawn, immediately
separated in a centrifuge, and frozen until testing.
To enhance subject compliance with study protocols, postpartum data collection was scheduled for the standard 4-week postnatal visit, rather than a later date. This study design was necessary because subjects were OSUCHS patients, a moderately transient population.
Assays to determine plasma concentrations of the various substances were performed at Regional Medical Lab Inc, also in Tulsa. Levels of TSH, FT4, and antibodies against thyroid peroxidase and thyroglobulin were all reported.
Instruments
The 10-item EPDS self-report scale was developed in Scotland in 1987 and is
easy for researchers to
score.8 A threshold
score of 12 or 13 is used to screen for possible depression. Test sensitivity
of the EPDS is reported as 86% with specificity reported at
78%.8
The test for TSH is a two-site sandwich immunoassay that uses direct chemiluminescence. With this method, there is a direct relationship between the amount of prolactin in a sample tested and the amount of relative light units detected by the system (ACS:Centaur 10440; Chiron Diagnostics, East Walpole, Mass).
The FT4 test used is a competitive immunoassay that uses direct chemiluminescence. The hormone to be tested competed with acridinium ester-labeled cortisol (ie, FT4) for binding to polyclonal rabbit antibody against the hormone of choice. With this method, an inverse relationship exists between the amount of hormone in a sample tested and the amount of relative light units detected by the system (ACS:Centaur 10440; Chiron Diagnostics, East Walpole, Mass). According to manufacturer guidelines, the normal range for FT4 is 0.65 ng/dL to 1.5 ng/dL. The instrument was carefully calibrated with control samples sent from the manufacturer before each batch of tests was run. According to the test's manufacturer, the normal range for TSH levels is 0.47 mIU/mL to 6.8 mIU/mL.
All tests were performed in summer 2000 by Regional Medical Lab Inc at St John Medical Center (Tulsa, Okla). The reference ranges and values came on the advice of the manufacturers via their Web sites.
The tests for both thyroglobulin antibody and peroxidase antibody were performed using a Biochem Personal Lab machine (Wampole Laboratories, Princeton, NJ) with enzyme immunoassay kits and reagent. A thyroglobulin antibody result greater than 19 IU/mL serum was considered positive. A peroxidase antibody result greater than 21 IU/mL serum was considered positive.
Statistical Analysis
The results were analyzed by simple linear regression so that depression
scores could be treated as a continuum rather than a dichotomy (ie,
"depressed" vs "not depressed"). Regressions were
performed separately for each of the independent variables to determine any
individual effects that each might have on EPDS scores.
| Results |
|---|
|
|
|---|
Thyroid-Stimulating Hormone
Only 7 of the 51 subjects had TSH values outside the normal range of 0.47
mIU/mL to 6.8 mIU/mL; 6 of these scores were low. The median TSH value was
1.251 mIU/mL, and the range was 0.11 mIU/mL to 10.12 mIU/mL. The standard
deviation was 1.3.
Subjects with higher serum TSH levels at 4 weeks postpartum tended also to have higher EPDS scores (P=.0416) (Figure 1). The correlation coefficient (r) was 0.286. The coefficient of determination, r2, was 0.082. In other words, about 8% of the variability of EPDS scores at 4 weeks postpartum is associated with the range of serum TSH values.
|
Thyroid Antibodies
Seven of the 51 subjects had positive thyroid antibody tests at 4 weeks
postpartum, though these were not necessarily the same 7 participants who had
abnormal TSH values. Three subjects had positive results for thyroid
antibodies during prenatal screening. The 7 participants with positive
antibody tests were more likely than their counterparts to have higher EPDS
scores (P=.0428) (Figure
2). The correlation coefficient, r, was 0.285. The
coefficient of determination, r2, was 0.0811. In other
words, about 8% of the variability of EPDS scores taken at 4 weeks postpartum
correlates with the variation in serum thyroid antibodies measured at that
time. On average, patients with positive thyroid antibody tests had maximum
EPDS scores that were almost 5 points higher than patients who did not have
similar laboratory results. Although the mean EPDS score for both groups was
still below 12, the thyroid antibody–positive group had greater
depressive symptomology.
|
No statistically significant correlation was found between TSH values and thyroid antibodies, r=0.1725 (P=.18). A power analysis revealed that, with 51 subjects from a population with an r2 of 0.10, a significant effect would be detected approximately 60% of the time. For an r2 of 0.15, a significant effect would be detected more than 80% of the time.10
| Comment |
|---|
|
|
|---|
Regarding the present study, Figure 1 might suggest that, for subjects whose EPDS scores are in the normal range, mood correlates somewhat with plasma TSH concentrations. However, for those who scored in the "depressed" range, any correlation does not seem to hold. We believe that small sample size may be, at least in part, responsible for these results. The "non-depressed" group (n=42) was more than four times as large as the "depressed" group (n=9) and would have a statistically greater chance of reflecting the average of the general population than their counterparts.
The simple linear regression of Figure 1 revealed two noteworthy items. First, the relationship between EPDS results and TSH had a statistically significant P value—such that these results could only occur by chance one in 20 times. Second, the graphed data do not appear to be linear, nor do they follow an easily identifiable pattern. It is obvious that lower EPDS scores and their corresponding lower TSH values are clustered. Perhaps a larger study would make it clear whether the relationship might actually be linear in nature.
Only 1 subject in this study group had a TSH value above the upper range of normal. However, a correlation between higher TSH levels at 4 weeks postpartum and higher EPDS scores is suggestive of a trend toward mood disruption and thyroid disturbance. Increasing EPDS scores reflect an increasing number of depressive symptoms even if the threshold for a positive depression screen is not reached. Further, depression is a known feature of subclinical hypothyroidism, occurring in perhaps 15% of cases.2 Although the etiology of thyroid disruption is unclear from the present data, association between mood state and thyroid hormone level is supported. However, our data show only associations and cannot support cause-and-effect relationships.
Elevated levels of antithyroid antibodies have been associated with PPD.3 Harris14 found an excess of depressive symptoms (though not major depression) in women who demonstrated thyroid antibodies in the first 8 months postpartum, even when conventional tests for thyroid dysfunction did not show abnormalities. Results also showed that women with thyroid antibody–positive results had higher mean scores for depression on several scales regardless of whether they became hypothyroid. Harris14 speculated that cytokines may be released as thyroid antibody concentrations increase after delivery and that these substances have an effect on the brain, causing many of the behaviors associated with PPD.
Our data may further support Harris' conclusions. In our study, 4 of the 7 subjects with thyroid antibody–positive test results had negative results during prenatal screening. In women who have other physiologic or psychosocial risk factors for PPD, the addition of a thyroid antibody element postnatally may become a clinically significant contributor to mood disorders.
Custro et al15 showed that, of 9 patients suffering from major depression, 5 individuals were subclinically hypothyroid. All 5 of these women tested positive for antibodies against thyroid peroxidase, thyroglobulin, or both, revealing a symptomless autoimmune thyroiditis. In contrast, none of the 70 subjects who were euthyroid and diagnosed as either severely depressed (n=4) or having minor depression (n=66) were seropositive for thyroid autoantibodies. These researchers15 suggested that major depression is accompanied by subclinical hypothyroidism in a significant proportion of women. Perhaps the possibility of autoimmune disease should be considered whenever women diagnosed with depression display biochemical thyroid dysfunction.
Researchers3 have found that about 3 in 100 women will have PPD that is related to positive thyroid antibody status and presence of normal blood levels of total and free triiodothyronine and FT4. Possible reasons for these findings include poor methodology and a general malaise due to the thyroiditis that is unrelated to actual thyroid hormone levels. A study by Harris3 may support the latter hypothesis. In that study, FT4 was administered prophylactically to women in the postpartum period with thyroid antibody–positive test results. These women were found to have depression just as often as their antibody-positive counterparts who did not receive FT4. Harris3 concluded that depression occurring in thyroid antibody–positive subjects was likely associated with malaise following the thyroid antibody–positive state rather than thyroid dysfunction. Another hypothesis16 for the etiology of depression mediated by thyroid antibodies maintains that activated leukocytes produce cytokines that cross the blood-brain barrier, attach to specific receptors, and mediate neurotransmission.
Limitations of the present study include the small sample size and limited data sampling—taking place prenatally and then at 4 weeks postpartum only, a relatively early point in the postpartum period. Further investigation with a larger study group and data collection at multiple postpartum intervals is warranted.
No data is available beyond the 4-week postpartum visit or regarding whether the volunteers who screened positive for PPD continued in that state, recovered, or had any other outcome. Out of ethical necessity, the women with positive EPDS results were immediately referred to a physician for counseling, antidepressants, or other treatment. Therefore, we could not determine whether their conditions changed as a result of some natural physiologic process or because of treatment. Later data would not have been comparable to early data, which reflected the natural coincidence of EPDS scores, TSH values, FT4 values, and thyroid antibody status.
| Conclusions |
|---|
|
|
|---|
| Acknowledgment |
|---|
| Footnotes |
|---|
Submitted September 13, 2007; revision received December 6, 2007; accepted December 19, 2007.
| References |
|---|
|
|
|---|
2. Pies R. The diagnosis and treatment of subclinical hypothyroid states in depressed patients [review]. Gen Hosp Psychiatry. 1997;19:344 -354. doi:10.1016/S0163-8343(97)00060-1 .[Medline]
3. Harris B. Postpartum depression and thyroid antibody status [review]. Thyroid.1999; 9:699 -703.[Medline]
4. Kuijpens JL, Vader HL, Drexhage HA, Wiersinga WM, van Son MJ, Pop VJ. Thyroid peroxidase antibodies during gestation are a marker for subsequent depression postpartum. Eur J Endocrinol. 2001;145:579-584. Available at: http://eje-online.org/cgi/reprint/145/5/579. Accessed August 27, 2008.
5. Oretti RG, Harris B, Lazarus JH, Parkes AB, Crownshaw T. Is there
an association between life events, postnatal depression and thyroid
dysfunction in thyroid antibody positive women? Int J Soc
Psychiatry. 2003;49:70
-76.
6. Lucas A, Pizarro E, Granada ML, Salinas I, Sanmartí A. Postpartum thyroid dysfunction and postpartum depression: are they two linked disorders? Clin Endocrinol.2001; 55: 809-814. doi: 10.1046/j.1365-2265.2001.01421.x.[Medline]
7. Harris B, Othman S, Davies JA, Weppner GJ, Richards CJ, Newcombe RG, et al. Association between postpartum thyroid dysfunction and thyroid antibodies and depression. BMJ. 1992;305:152-156. Available at: http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1883200&blobtype=pdf. Accessed August 27, 2008.
8. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression
development of the 10-item Edinburgh postnatal depression scale. Br
J Psychiatry. 1987;150:782
-786.
9. Fisher J, Astbury J, Smith A. Adverse psychological impact of operative obstetric interventions: a prospective longitudinal study. Aust N Z J Psychiatry.1997; 31:728 -738.[Medline]
10. Murphy KR, Myors B. Statistical Power Analysis: A Simple and General Model for Traditional and Modern Hypothesis Tests. Mahwah, NJ: Lawrence Erlbaum Associates; 2004:160 .
11. Harris B, Fung H, Johns S, Kologlu M, Bhatti R, McGregor A, et al. Transient postpartum thyroid dysfunction and postnatal depression. J Affect Disord.1989; 17:243 -249.[Medline]
12. Pop VJ, de Rooy HJ, Vader HL, van der Heide D, van Son M, Komproe IH, Essed GG, de Gues CA. Postpartum thyroid dysfunction and depression. N Engl J Med.1991; 324:1815 -1816.[Medline]
13. Lazarus JH, Ammari F, Oretti R, Parkes AB, Richards CJ, Harris B. Clinical aspects of recurrent postpartum thyroiditis. Br J Gen Pract. 1997;41:305-308. Available at: http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1313006&blobtype=pdf. Accessed August 27, 2008.
14. Harris B. A hormonal component to postnatal depression.
Br J Psychiatry.1993; 163:403
-405.
15. Custro N, Scafidi V, Lo Baido R, Nastri L, Abbate G, Cuffaro MP, et al. Subclinical hypothyroidism resulting from autoimmune thyroiditis in female patients with endogenous depression. J Endocrinol Invest. 1994;17:641 -646.[Medline]
16. Leonard BE, Song C. Stress, depression, and the role of cytokines [review]. Adv Exp Med Biol.1999; 461:251 -265.[Medline]
17. Kumar R. Anybody's child: Severe disorders of mother-to-infant
bonding. Br J Psychiatry.1997; 171:175
-181.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |